FDA advisory panel recommends AstraZeneca’s Truqap combination for PTEN-deficient prostate cancer

On 2026-05-01, the U.S. FDA's Oncologic Drugs Advisory Committee recommended approval of AstraZeneca's Truqap in combination with abiraterone and androgen deprivation therapy for PTEN-deficient metastatic hormone-sensitive prostate cancer. The recommendation concerns a treatment milestone in the United States based on the CAPItello-281 trial results.